1. Home
  2. KYN vs AMLX Comparison

KYN vs AMLX Comparison

Compare KYN & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kayne Anderson Energy Infrastructure Fund Inc.

KYN

Kayne Anderson Energy Infrastructure Fund Inc.

HOLD

Current Price

$14.06

Market Cap

2.5B

Sector

Finance

ML Signal

HOLD

Logo Amylyx Pharmaceuticals Inc.

AMLX

Amylyx Pharmaceuticals Inc.

HOLD

Current Price

$21.83

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KYN
AMLX
Founded
2004
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.0B
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
KYN
AMLX
Price
$14.06
$21.83
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$21.56
AVG Volume (30 Days)
370.4K
1.8M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
8.99%
N/A
EPS Growth
N/A
65.46
EPS
N/A
N/A
Revenue
N/A
$380,786,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$20.75
N/A
Revenue Growth
N/A
1612.94
52 Week Low
$11.31
$7.48
52 Week High
$15.17
$22.28

Technical Indicators

Market Signals
Indicator
KYN
AMLX
Relative Strength Index (RSI) 44.02 72.08
Support Level $13.62 $12.14
Resistance Level $14.35 N/A
Average True Range (ATR) 0.26 1.29
MACD -0.07 0.27
Stochastic Oscillator 8.95 92.53

Price Performance

Historical Comparison
KYN
AMLX

About KYN Kayne Anderson Energy Infrastructure Fund Inc.

Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.

About AMLX Amylyx Pharmaceuticals Inc.

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

Share on Social Networks: